Skip to main
RNA
RNA logo

Avidity Biosciences (RNA) Stock Forecast & Price Target

Avidity Biosciences (RNA) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Avidity Biosciences Inc demonstrates a strong foundation for a positive outlook based on its recent clinical trial data, particularly with the 10 mg/kg dose of del-zota, which exhibited a statistically significant 43% improvement in exon skipping and a noteworthy restoration of dystrophin production levels. The consistent improvements across key biomarkers, including the reported increases in dystrophin production and creatinine kinase, underscore the efficacy and safety profile of its Antibody Oligonucleotide Conjugates (AOCs) approach. Furthermore, the encouraging data across both ambulatory and non-ambulatory participants suggests a comprehensive therapeutic benefit, bolstering the potential for successful registrational outcomes for its developmental programs in Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD).

Bears say

Avidity Biosciences faces significant risks that could adversely impact its stock outlook, particularly if its ongoing and future clinical trials yield negative results, which would exert downward pressure on share prices. Additionally, the potential for new treatment methods to emerge that could overshadow Avidity's therapies raises concerns about the competitiveness and market viability of its offerings. Finally, challenges related to the adequacy of key intellectual property protections and potential legal issues could introduce substantial financial burdens, further complicating Avidity's market position.

Avidity Biosciences (RNA) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avidity Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avidity Biosciences (RNA) Forecast

Analysts have given Avidity Biosciences (RNA) a Buy based on their latest research and market trends.

According to 22 analysts, Avidity Biosciences (RNA) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.49, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.49, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avidity Biosciences (RNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.